secwatch.observer — SEC 8-K summary
======================================

Issuer:     Trevi Therapeutics, Inc. (TRVI)
CIK:        0001563880
Form:       8-K
Filed at:   2024-11-06T23:59:59+00:00
Accession:  0000950170-24-122316
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Trevi Therapeutics reports Q3 net loss of $13.2M; completes Phase 2a RIVER enrollment
--------------------------------------------------------------------------------

- Net loss of $13.2M for Q3 2024 vs $7.7M loss in Q3 2023; R&D expenses rose to $11.2M from $6.3M.
- Cash, cash equivalents and marketable securities of $65.5M at quarter end; expected runway into H2 2026.
- Completed enrollment in Phase 2a RIVER trial for refractory chronic cough; topline results expected Q1 2025.
- Enrolled 50% of planned 160 patients in Phase 2b CORAL trial for chronic cough in IPF; SSRE outcome expected Dec 2024; topline H1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563880/000095017024122316/0000950170-24-122316-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563880/000095017024122316/trvi-20240808.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-122316

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer